There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Arrowhead Pharmaceuticals (ARWR), NeuBase Therapeutics (NBSE) and Knight Therapeutics (KHTRF) with bullish sentiments.
Arrowhead Pharmaceuticals (ARWR)
In a report issued on May 17, Luca Issi from RBC Capital maintained a Buy rating on Arrowhead Pharmaceuticals, with a price target of $90.00. The company’s shares closed last Tuesday at $72.26.
According to TipRanks.com, Issi has 0 stars on 0-5 stars ranking scale with an average return of -16.7% and a 19.2% success rate. Issi covers the Healthcare sector, focusing on stocks such as Adverum Biotechnologies, Crispr Therapeutics AG, and Ionis Pharmaceuticals.
Currently, the analyst consensus on Arrowhead Pharmaceuticals is a Strong Buy with an average price target of $81.25, implying a 9.9% upside from current levels. In a report issued on May 5, Chardan Capital also maintained a Buy rating on the stock.
See today’s analyst top recommended stocks >>
NeuBase Therapeutics (NBSE)
In a report issued on May 14, Brian Abrahams from RBC Capital maintained a Buy rating on NeuBase Therapeutics, with a price target of $16.00. The company’s shares closed last Tuesday at $5.21, close to its 52-week low of $4.51.
According to TipRanks.com, Abrahams is a 4-star analyst with an average return of 6.0% and a 47.1% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Intra-Cellular Therapies, and Karyopharm Therapeutics.
NeuBase Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $17.00, implying a 233.3% upside from current levels. In a report issued on May 17, Chardan Capital also reiterated a Buy rating on the stock with a $18.00 price target.
Knight Therapeutics (KHTRF)
In a report issued on May 14, Douglas Miehm from RBC Capital maintained a Buy rating on Knight Therapeutics, with a price target of C$7.50. The company’s shares closed last Monday at $4.44.
According to TipRanks.com, Miehm is a 1-star analyst with an average return of 0.0% and a 41.0% success rate. Miehm covers the Healthcare sector, focusing on stocks such as Bausch Health Companies, Aurinia Pharmaceuticals, and Medical Facilities.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Knight Therapeutics with a $6.59 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
